Publications by authors named "Takatoshi Isiko"
Article Synopsis
- * A study focused on 20 high-risk, unresectable CRLM patients treated with hepatectomy and optional local ablation; outcomes showed that all patients responded positively to chemotherapy, with low recurrence rates after surgery.
- * The findings indicate that the treatment approach for high-risk patients is effective, achieving a 3-year disease-free survival rate of 57.4% and a 5-year overall survival rate of 56.2%, regardless of whether local ablation was included.
It has been reported that patients with macroscopic vascular invasion accompanying hepatocellular carcinoma have a poor prognosis. Modern molecular therapy with multitargeted tyrosine kinase inhibitors and immune checkpoint inhibitors has shown promising results in patients with metastatic hepatocellular carcinoma; however, molecular therapy is limited to patients with Child-Pugh class A disease. This review summarizes the present status of surgical therapies, including conversion hepatectomy, for patients with MVI in the developing era of novel molecular therapy.
View Article and Find Full Text PDFArticle Synopsis
- Patients with bilateral lung metastases from hepatocellular carcinoma (HCC) typically receive molecular therapy, with atezolizumab and bevacizumab showing potential for long-term survival.
- A 67-year-old woman treated for HCC experienced metastases in her lungs and underwent multiple therapies, including lenvatinib, atezolizumab plus bevacizumab, and later cabozantinib and dual immune checkpoint inhibitors.
- Despite limited response from some treatments, she maintained stable disease for extended periods while preserving liver function and quality of life.
Background/aim: Operable peritoneal dissemination from distal cholangiocarcinoma after pancreaticoduodenectomy is rare. Furthermore, peritoneal dissemination mimicking liver metastasis has scarcely been reported.
Case Report: An 81-year-old woman received pancreaticoduodenectomy for distal cholangiocarcinoma.
Article Synopsis
- Hepatocellular carcinoma (HCC) associated with bile duct tumor thrombus (BDTT) is aggressive, requiring ongoing, multidisciplinary treatment approaches for effective management.
- The study presented two cases of elderly men with advanced HCC and BDTT, who underwent complex surgical and interventional therapies, including extended liver surgeries and transarterial chemoembolization (TACE).
- Both patients achieved complete remission without viable tumors and maintained good health nearly two years post-treatment, highlighting the effectiveness of the Vater papilla-preserving strategy for long-term survival in such cases.
Aim: The aim of this study was to determine whether antiviral therapy with nucleotide/nucleoside analog (NA) is beneficial for Japanese patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) who underwent initial curative liver resection.
Patients And Methods: In 162 patients with positive hepatitis B surface antigen and negative anti-hepatitis C virus antibody, sixty-two patients received antiviral therapy with NA (NA group) and the remaining 100 patients did not (non-NA group). Prognostic factors for disease-free survival (DFS) and overall survival (OS) were evaluated.
Massive hemorrhage from an adrenocortical carcinoma seldom occurs in the retroperitoneal or abdominal cavity. We report a case of spontaneous rupture of primary adrenocortical carcinoma occurring in an adolescent. A right adrenalectomy with complete removal of the tumor was performed successfully.
View Article and Find Full Text PDFA 75-year-old man with right chest pain was diagnosed with primary lung cancer in the right apical portion, and was treated with chemoradiotherapy because of a synchronous left adrenal tumor of 1.6 cm. Since the adrenal tumor did not increase in size for three months and there were no other relapses, the right upper lobectomy of the lung with the excision of the chest wall was performed.
View Article and Find Full Text PDFWe have developed a new therapeutic modality: laparoscopic devascularization (LDEV) for hepatocellular carcinoma (HCC). Thirteen patients with HCC were treated with LDEV from March 1998 to March 2002. All LDEV procedures were performed under laparoscopic surgery using laparoscopic coagulating shears (LCS), endo-clip and endo-GIA.
View Article and Find Full Text PDF